AQR Capital Management
OREX

AQR Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

AQR Capital Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,306
Closed -$312K – 2375
2015
Q2 		$312K Buy
+6,306
New +$377K ﹤0.01% 1970
2013
Q4 		– Sell
-7,757
Closed -$476K – 2727
2013
Q3 		$476K Sell
7,757
-13,070
-63% -$885K ﹤0.01% 2001
2013
Q2 		$1.22M Buy
+20,827
New +$1.28M ﹤0.01% 1475

Other funds holding OREX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management's OREX Position: Q3 2015 in Review

AQR Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 6,306 shares — an estimated $312K sold.

AQR Capital Management first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $1.22M in Q2 2013. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

  • AQR Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • AQR Capital Management sold 6,306 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $312K.
  • AQR Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • AQR Capital Management's Orexigen Therapeutics, Inc. position peaked at $1.22M in Q2 2013.
  • 132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on AQR Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.